comparison with bare metal stents in diabetic patients. 7 Among the 1 st generation DES, SES is safe, effecious and superior than compare to PES in patient with diabetes. 8 Among the 2 nd generation DES, Everolimus is not inferior to SES in reducing angiographic restenosis and clinical outcome. 9 Data on Multiple or overlapping stent in a single vessel territory in diabetic Bangladeshi is not yet available. Therefore, the aim of our present study was to assess primarily the longterm patency of multiple or overlapping stent in patient with Diabetes Mellitus (DM) and Nondiabetes Mellitus (NDM).
Methods:
Patients were selected from those who underwent routine coronary angiogram for further evaluation of their coronary status. Most of the patient population in this study had percutaneous coronary intervention (PCI) either with bare metal stent or drug eluting stent in the preceding 3-36months. Eligible patients had a history of stable or unstable angina or documented / silent myocardial infarction. The target lesion for study was an instent coronary arterial lesion between 15 mm and 40 mm with 2.5-4.0 mm in diameter.
Procedure: CAG was performed as per standard protocol. Individual discretion was applied as per operator's choice, depending on patient's problem. Details of the previous procedure were collected from patient's old papers. These included indication, stent detail, complication etc. Whenever possible, old angiogram was also reviewed and compared to the current cine angiogram.
Data: Data were presented as mean ± SD with percentage. Edge re-stenosis was defined as greater than 50% narrowing in the 5mm immediate or distal to the treated region. ISR of significance was also defined as >50% was of lumen inside the stent.
Results:
Our results show that, 11% (51) patient has multiple stent in single coronary territory. Among the studied population, 41 were Male and 8 were female. 
Discussion:
Data on overlapping or multiple stent in a single coronary artery territory in Bangladeshi patient population are not available. Among the different stents, which stent type is suitable in diabetic patient with increase stent patency and reduced ISR were not well known. Investigator has shown, that Drug eluting stents significantly reduced angiographic restenosis and cardiac events compared with BMS in Diabetic patients. 8 In the era of DES, Presence of DM associated with higher neointimal hyperplasia, restenosis and unfavorable clinical outcomes. 10 Moreover, diabetic patients often present unfavorable coronary anatomy with small and/ or diffusely diseased vessel 11 and exhibit exaggerated neointimal hyperplasia after bare metal stent implantation than compared to nondiabetic patients. 12 Although DES significantly reduced the neointimal hyperplasia and angiographic restenosis compared with bare metal stents in DM patients, 8 the presence of DM continues to be associated with an increased risk of restenosis and unfavorable clinical outcomes in the DES era. 13 Several studies has shown, that SES to have promising efficacy than compare with PES in DM patients. 14 16 Even, in longer lesion of patient with DM, SES shown its superiority over PES than ISAR-DIABTES. 17 Kim WJ 9 has shown that the 2 nd generation Everolimus Eluting stents were non inferior to Sirolimus-eluting stents in reducing in-segment late loss reduced angiographic restenosis at 8 months in patients with diabetes mellitus and coronary artery disease.
We found that the 1 st generation Sirolimus Eluting stent has reduced instent restenosis with increased stent patency for the designated period of 3.1yrs.
Because of the very small number, the long-term patency of the 2 nd generation drug eluting stent with reduced ISR was not understood well. In this, regard we need more Diabetic patient inclusion and carried out comparative study.
It is well known that Diabetes mellitus has been reported to be associated with antiplatelet resistance. 18 This is explained by aggressive atherosclerosis, abnormal endothelial function, impaired fibrinolysis, increased platelet activity is considered critically involved in the increased thrombogenic potential among diabetic patients. These findings might be associated with an increased risk of stent thrombosis after coronary stenting. 19 To treat long lesion, operators favor an overlap strategy because of the practical difficulties with abutting stents, coupled with concerned over gaps or genomic miss. The biologics effects of multiple drug dosing may also impact on the vascular biology of patients. Theoretical concerns related to the use of overlapping drug-eluting stents include the potential toxic effect of increased doses of a drug on vascular endothelium 20 which may result in positive remodeling and aneurysm formation, and possible late stent thrombosis as a consequence of incomplete re-endothelization. Potential adverse reactions to a polymer delivery system in terms of implantation and thrombogenic effects 21 any also increase with overlapping stents.
Conclusion:
Overlapping stents in a single coronary artery lesion carries a risk of restenosis, especially in patient population of diabetes mellitus. Several studies have shown the promising result of different DES in treating long, diffuse and small in caliber coronary of diabetes patient. Among them, many has shown the potential better outcome with reduced ISR in Cypher Sirolimus eluting stent and non-inferior results by 2 nd generation Everolimus-eluting stent. It is difficult to conclude in this present prospective cohort which DES is better in our patient with diabetes mellitus. We need more data and multicenter registry in Bangladesh.
Study Limitation:
Most of our studied patients had their PCI done either with BMS or DES in other centers. We had to depend on the reports provided by the patients.
Although they all included stent details, procedural details were missing. We eventually got only information about the type of stent used and few other details.
